

US Blood Cancer Drug Market & Pipeline Analysis 2015

<https://marketpublishers.com/r/UFE551ACC3AEN.html>

Date: July 2015

Pages: 1100

Price: US\$ 3,000.00 (Single User License)

ID: UFE551ACC3AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood cancer incidences, high unmet medical necessities and demand for better therapeutics are some major factors behind growth of US blood cancer market segment. Higher investments have been made by pharmaceutical companies in order to come forth with better therapeutics for generating significant revenues. As a result, numerous therapeutic have been introduced in US market for the successful treatment of blood cancer. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.

Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs.

Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has

received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior than chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market.

Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase.

'US Blood Cancer Drug Market & Pipeline Analysis 2015' Report Highlights:

Blood Cancer Incidence & Prevalence

Blood Cancer Drug Market Overview

Blood Cancer Drug Market Dynamics

Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight

Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs

Majority Drugs in Phase-I Clinical Trials: 128 Drugs

Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis

Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs

Contents

1. US BLOOD CANCER INCIDENCE & PREVALENCE

1.1 Leukemia: Cancer of White Blood Cells (WBC)

- 1.1.1 Acute Lymphocytic Leukemia (ALL)
- 1.1.2 Acute Myeloid Leukemia (AML)
- 1.1.3 Chronic Lymphocytic Leukemia (CLL)
- 1.1.4 Chronic Myeloid Leukemia (CML)

1.2 Lymphoma: Cancer of Lymphatic System

- 1.2.1 Hodgkin Lymphoma
- 1.2.2 Non-Hodgkin Lymphoma (NHL)

1.3 Myeloma

2. US BLOOD CANCER DRUG MARKET OVERVIEW

2.1 Current Market Scenario

2.2 US Blood Cancer Drug Clinical Pipeline Overview

3. US BLOOD CANCER DRUG MARKET DYNAMICS

3.1 Favorable Market Parameters

3.2 Commercialization Challenges

4. US BLOOD CANCER DRUG MARKET FUTURE PROSPECTS

5. MECHANISM OF BLOOD CANCER THERAPEUTICS

6. LEUKEMIA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

6.1 Research till Registered

6.2 Discontinued & Suspended Leukemia Drug Clinical Insight

7. MARKETED LEUKEMIA DRUG CLINICAL INSIGHT

7.1 Alemtuzumab (Campath)

7.2 Arsenic Trioxide (Trisenox)

7.3 Bosutinib (Bosulif)

7.4 Clofarabine

- 7.5 Crisantaspase (Erwinaze)
- 7.6 Dasatinib (Sprycel)
- 7.7 Fludarabine (Fludara)
- 7.8 Idarubicin (Idamycin)
- 7.9 Imatinib (Gleevec)
- 7.10 Irinotecan
- 7.11 Mercaptopurine Oral Suspension (Purixan™)
- 7.12 Mitoxantrone (Novantrone)
- 7.13 Nilotinib (Tasigna)
- 7.14 Obinutuzumab (Gazyva)
- 7.15 Ofatumumab (Arzerra)
- 7.16 Omacetaxine Mepesuccinate (Synribo)
- 7.17 Pegaspargase (Oncaspar)
- 7.18 Pentostatin (Nipent)
- 7.19 Ponatinib (Iclusig)
- 7.20 Sargramostim (Leukine)
- 7.21 Tretinoin
- 7.22 Vincristine Liposomal - Spectrum Pharmaceuticals (Marqibo)

8. LYMPHOMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

- 8.1 Research till Registered
- 8.2 Discontinued & Suspended Lymphoma Drug Clinical Insight

9. MARKETED LYMPHOMA DRUG CLINICAL INSIGHT

- 9.1 Belinostat (Beleodaq)
- 9.2 Bexarotene Oral (Targretin)
- 9.3 Bexarotene Topical (Targretin)
- 9.4 Brentuximab Vedotin (Adcetris)
- 9.5 Chlormethine (Valchlor™)
- 9.6 Denileukin Diftitox (ONTAK)
- 9.7 Ibritumomab Tiuxetan (Zevalin)
- 9.8 Interferon Alpha-2b (Intron A)
- 9.9 Pralatrexate (Folotyn)
- 9.10 Romidepsin (Istodax)
- 9.11 Vorinostat (Zolinza)

10. MULTIPLE MYELOMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

10.1 Research till Preregistration

10.2 Discontinued & No Development Reported in Multiple Myeloma Drug Clinical Insight

11. MARKETED MULTIPLE MYELOMA DRUG CLINICAL INSIGHT

11.1 Carfilzomib (Kyprolis)

11.2 Doxorubicin Liposomal – ALZA

11.3 Pomalidomide (Pomalyst)

11.4 Thalidomide (Thalomid)

11.5 Zoledronic Acid (Zometa)

12. MULTIPLE BLOOD CANCER DRUG CLINICAL PIPELINE BY COMPANY & PHASE

12.1 Research till Preregistration

12.2 Discontinued & Suspended Multiple Blood Cancer Drug Clinical Insight

13. MARKETED MULTIPLE BLOOD CANCER DRUG CLINICAL INSIGHT

13.1 Azacitidine (Vidaza)

13.2 Bendamustine (Treanda)

13.3 Bortezomib (Velcade)

13.4 Cladribine (Leustatin)

13.5 Decitabine (Dacogen)

13.6 Ibrutinib (Imbruvica)

13.7 Idelalisib

13.8 Lenalidomide (Revlimid)

13.9 Nelarabine (Arranon)

13.10 Rituximab (Rituxan)

14. COMPETITIVE LANDSCAPE

14.1 Actelion Pharmaceuticals

14.2 Amgen

14.3 ARIAD Pharmaceuticals

14.4 Astellas Pharma

14.5 Baxter BioScience

- 14.6 Bayer HealthCare Pharmaceuticals Inc.
- 14.7 Biogen Idec
- 14.8 Bristol-Myers Squibb
- 14.9 CASI Pharmaceuticals
- 14.10 Celera Genomics Group
- 14.11 Celgene Corporation
- 14.12 Eisai Co Ltd
- 14.13 Genmab
- 14.14 Gilead Sciences
- 14.15 GlaxoSmithKline
- 14.16 Hospira
- 14.17 Johnson & Johnson
- 14.18 Millennium Pharmaceuticals
- 14.19 Nova Laboratories
- 14.20 Novartis
- 14.21 Onxeo SA
- 14.22 Onyx Pharmaceuticals
- 14.23 Otsuka Pharmaceutical
- 14.24 Pfizer
- 14.25 Roche
- 14.26 Scripps Clinic
- 14.27 Seattle Genetics
- 14.28 SRI International
- 14.29 Southern Research Institute
- 14.30 Tekmira Pharmaceuticals Corporation
- 14.31 Teva Pharmaceutical Industries
- 14.32 Yakult Honsha

List Of Figures

LIST OF FIGURES

Figure 1-1: Main Types of Blood Cancer

Figure 1-2: Percentage of Leukemia in New Cancer Cases, 2015

Figure 1-3: Percentage of Leukemia in all Cancer Related Deaths, 2015

Figure 1-4: Leukemia Estimated Cases, 2013-2015

Figure 1-5: Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-6: Leukemia Estimated New Cases in Females, 2013-2015

Figure 1-7: Leukemia Estimated Deaths, 2013-2015

Figure 1-8: Leukemia Estimated Deaths in Males, 2013-2015

Figure 1-9: Leukemia Estimated Deaths in Females, 2013-2015

Figure 1-10: Percentage of Acute Lymphocytic Leukemia in Cancer Related Deaths, 2015

Figure 1-11: Percentage of Acute Lymphocytic Leukemia in New Cancer Cases, 2015

Figure 1-12: Acute Lymphocytic Leukemia Estimated New Cases, 2013-2015

Figure 1-13: Acute Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-14: Acute Lymphocytic Leukemia Estimated New Cases in Female, 2013-2015

Figure 1-15: Acute Lymphocytic Leukemia Estimated Deaths, 2013-2015

Figure 1-16: Acute Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015

Figure 1-17: Acute Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015

Figure 1-18: Acute Myeloid Leukemia Estimated New Cases, 2013-2015

Figure 1-19: Acute Myeloid Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-20: Acute Myeloid Leukemia Estimated New Cases in Females, 2013-2015

Figure 1-21: Percentage of Acute Myeloid Leukemia in New Cancer Cases, 2015

Figure 1-22: Percentage of Acute Myeloid Leukemia in all Cancer Deaths, 2015

Figure 1-23: Acute Myeloid Leukemia Estimated Deaths, 2013-2015

Figure 1-24: Acute Myeloid Leukemia Estimated Deaths in Male, 2013-2015

Figure 1-25: Acute Myeloid Leukemia Estimated Deaths in Female, 2013-2015

Figure 1-26: Chronic Lymphocytic Leukemia Estimated New Cases, 2013-2015

Figure 1-27: Chronic Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015

Figure 1-28: Chronic Lymphocytic Leukemia Estimated New Cases in Females, 2013-2015

Figure 1-29: Chronic Lymphocytic Leukemia Estimated Deaths, 2013-2015

Figure 1-30: Percentage of Chronic Lymphocytic Leukemia in New Cancer Cases, 2015

Figure 1-31: Percentage of Chronic Lymphocytic Leukemia in all Cancer Related Deaths, 2015

- Figure 1-32: Chronic Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
- Figure 1-33: Chronic Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
- Figure 1-34: Percentage of Chronic Myeloid Leukemia in New Cancer Cases, 2015
- Figure 1-35: Percentage of Chronic Myeloid Leukemia in all Cancer Related Deaths, 2015
- Figure 1-36: Categories of Chronic Myeloid Leukemia (CML)
- Figure 1-37: Chronic Myeloid Leukemia Estimated New Cases, 2013-2015
- Figure 1-38: Estimated New Cases of Chronic Myeloid Leukemia in Males, 2013-2015
- Figure 1-39: Estimated New Cases of Chronic Myeloid Leukemia in Females, 2013-2015
- Figure 1-40: Estimated Deaths due to Chronic Myeloid Leukemia, 2013-2015
- Figure 1-41: Estimated Deaths due to Chronic Myeloid Leukemia in Male, 2013-2015
- Figure 1-42: Estimated Deaths due to Chronic Myeloid Leukemia in Female, 2013-2015
- Figure 1-43: Types of Lymphoma
- Figure 1-44: Identification of Different Types of Lymphomas
- Figure 1-45: Lymphoma Estimated New Cases, 2013-2015
- Figure 1-46: Estimated New Cases of Lymphoma in Males, 2013-2015
- Figure 1-47: Estimated New Cases of Lymphoma in Females, 2013-2015
- Figure 1-48: Estimated Lymphoma Deaths, 2013-2015
- Figure 1-49: Lymphoma Estimated Deaths in Males, 2013-2015
- Figure 1-50: Lymphoma Estimated Deaths in Females, 2013-2015
- Figure 1-51: Percentage of Hodgkin Lymphoma in New Cancer Cases, 2015
- Figure 1-52: Percentage of Hodgkin Lymphoma in all Cancer Related Deaths, 2015
- Figure 1-53: Estimated New Cases of Hodgkin Lymphoma, 2013-2015
- Figure 1-54: Estimated New Cases of Hodgkin Lymphoma in Male, 2013-2015
- Figure 1-55: Estimated New Cases of Hodgkin Lymphoma in Females, 2013-2015
- Figure 1-56: Hodgkin Lymphoma Estimated Deaths, 2013-2015
- Figure 1-57: Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
- Figure 1-58: Hodgkin Lymphoma Estimated Deaths in Female, 2013-2015
- Figure 1-59: Percentage of Non-Hodgkin Lymphoma (NHL) in New Cancer Cases, 2015
- Figure 1-60: Percentage of Non-Hodgkin Lymphoma in all Cancer Related Deaths, 2015
- Figure 1-61: Non-Hodgkin Lymphoma Estimated New Cases, 2013-2015
- Figure 1-62: Non-Hodgkin Lymphoma Estimated New Cases in Male, 2013-2015
- Figure 1-63: Non-Hodgkin Lymphoma Estimated New Cases in Female, 2013-2015
- Figure 1-64: Non-Hodgkin Lymphoma Estimated Deaths, 2013-2015
- Figure 1-65: Non-Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
- Figure 1-66: Non-Hodgkin Lymphoma Estimated Deaths in Females, 2015- 2013
- Figure 1-67: Percentage of Myeloma in New Cancer Cases, 2015

- Figure 1-68: Myeloma Estimated New Cases, 2013-2015
- Figure 1-69: Myeloma Estimated New Cases in Males, 2013-2105
- Figure 1-70: Myeloma Estimated New Cases in Females, 2013-2015
- Figure 1-71: Percentage of Myeloma in all Cancer Related Deaths, 2015
- Figure 1-72: Myeloma Estimated Deaths, 2013-2015
- Figure 1-73: Myeloma Estimated Deaths in Males, 2013-2015
- Figure 1-74: Myeloma Estimated Deaths in Females, 2013-2015
- Figure 2-1: Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-2: Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-3: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-4: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-5: Discontinued Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-6: Discontinued Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-7: Suspended Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-8: Suspended Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-9: Leukemia Drug Pipeline Overview by Phase (%), 2015
- Figure 2-10: Leukemia Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-11: No Development Reported Leukemia Drug Pipeline Overview by Phase (%), 2015
- Figure 2-12: No Development Reported Leukemia Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-13: Discontinued Leukemia Drug Pipeline Overview by Phase (%), 2015
- Figure 2-14: Discontinued Leukemia Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-15: Suspended Leukemia Drug Pipeline Overview by Phase (%), 2015
- Figure 2-16: Suspended Leukemia Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-17: Lymphoma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-18: Lymphoma Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-19: No Development Reported Lymphoma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-20: No Development Reported Lymphoma Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-21: Discontinued Lymphoma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-22: Discontinued Lymphoma Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-23: Suspended Lymphoma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-24: Suspended Lymphoma Drug Pipeline Overview by Phase (Number), 2015

- Figure 2-25: Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-26: Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-27: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-28: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-29: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
- Figure 2-30: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-31: Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-32: Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-33: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-34: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-35: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-36: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 2-37: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
- Figure 2-38: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
- Figure 3-1: US Blood Cancer Drug Market Favorable Parameters
- Figure 3-2: US Blood Cancer Drug Market Commercialization Challenges
- Figure 5-1: Mechanism of Idelalisib
- Figure 5-2: Mechanism of Imatinib
- Figure 5-3: Mechanism of Rituximab
- Figure 5-4: Mechanism of Doxorubicin
- Figure 5-5: Mechanism of Carfilzomib
- Figure 14-1: Actelion Pharmaceuticals Clinical Pipeline
- Figure 14-2: Amgen Clinical Pipeline
- Figure 14-3: ARIAD Clinical Pipeline
- Figure 14-4: Casi Pharmaceutical Clinical Pipeline
- Figure 14-5: Celgene Clinical Pipeline
- Figure 14-6: Gilead Sciences Clinical Pipeline
- Figure 14-7: GalaxoSmithKline Clinical Pipeline
- Figure 14-8: Millennium Pharmaceuticals Clinical Pipeline

Figure 14-9: Novartis Clinical Pipeline
Figure 14-10: Onxeo SA Clinical Pipeline
Figure 14-11: Roche Clinical Pipeline
Figure 14-12: Tekmira Clinical Pipeline

COMPANIES

Actelion Pharmaceuticals,
Amgen,
ARIAD Pharmaceuticals,
Astellas Pharma,
Baxter BioScience,
Bayer HealthCare Pharmaceuticals Inc.,
Biogen Idec,
Bristol-Myers Squibb,
CASI Pharmaceuticals,
Celera Genomics Group,
Celgene Corporation,
Eisai Co Ltd,
Genmab,
Gilead Sciences,
GlaxoSmithKline,
Hospira,
Johnson & Johnson,
Millennium Pharmaceuticals,
Nova Laboratories,
Novartis,
Onxeo SA,
Onyx Pharmaceuticals,
Otsuka Pharmaceutical,
Pfizer,
Roche,
Scripps Clinic,
Seattle Genetics,
SRI International,
Southern Research Institute,
Tekmira Pharmaceuticals Corporation,
Teva Pharmaceutical Industries,
Yakult Honsha

I would like to order

Product name: US Blood Cancer Drug Market & Pipeline Analysis 2015

Product link: <https://marketpublishers.com/r/UFE551ACC3AEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UFE551ACC3AEN.html>